We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Kaleido Biosciences Warned by FDA for Failing to Submit INDs
Kaleido Biosciences Warned by FDA for Failing to Submit INDs
Despite contending that it didn’t need to submit investigational new drug (IND) applications for two COVID-19 trials of its novel glycan candidate, KB109, Kaleido Biosciences received a warning letter from the FDA explaining that it did in fact need to submit one.